Phaseline

Companies › EyeD Pharma

EyeD Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Timolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1GlaucomaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07036510TimololPhase 1GlaucomaOphthalmologyJan 2027

Targets

ADRB1 (1) ADRB2 (1)

Companies with the same targets

Chiesi Farmaceutici AstraZeneca Actimed Therapeutics ARS Pharmaceuticals Acer Therapeutics GSK Tecnoquimicas Lunan Better Pharmaceutical Polarean Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.